New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
09:55 EDTGALEGalena 'stands little chance' of improving Zuplenz sales, TheStreet says
After Galena BioPharma entered into a license agreement with MonoSol Rx for Zuplenz, TheStreet's Adam Feuerstein predicted that the company "stands little chance of delivering higher sales of Zuplenz than its previous marketer," calling the drug one that "no one wants" and "something to promote while waiting for the phase III study of NeuVax in breast cancer to inevitably fail." Reference Link
News For GALE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for GALE

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use